Buy or sell IGM Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

IGM Biosciences Stock

Develops antibodies for treatment of cancer

Founded

2010

Headquarters

Mountain View CA, US

Total Funding

$102M

About IGM Biosciences Stock

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that is focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies, and IGM believes it has the most advanced research and development program focused on engineered IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent advantages may provide superior performance, as compared to IgG antibodies. For more information about IGM Biosciences, its technologies and its antibody pipeline, please visit www.igmbio.com.

Funding History

July 2019$102M

Management

CEO

Fred M. Schwarzer

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from IGM Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo